Pharmaceutical care for severe and critically ill patients with COVID-19.

Saiping Jiang; Lu LI; Renping RU; Chunhong Zhang; Yuefeng Rao; Bin Lin; Rongrong Wang; Na Chen; Xiaojuan Wang; Hongliu Cai; Jifang Sheng; Jianying Zhou; Xiaoyang LU; Yunqing Qiu

Return

Pharmaceutical care for severe and critically ill patients with COVID-19.

Author: Saiping JIANG ¹ ; Lu LI ¹ ; Renping RU ² ; Chunhong ZHANG ³ ; Yuefeng RAO ¹ ; Bin LIN ⁴ ; Rongrong WANG ¹ ; Na CHEN ¹ ; Xiaojuan WANG ¹ ; Hongliu CAI ¹ ; Jifang SHENG ¹ ; Jianying ZHOU ¹ ; Xiaoyang LU ¹ ; Yunqing QIU ¹
Author Information

1. The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
2. Hangzhou Xixi Hospital, Hangzhou 310023, China.
3. The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China.
4. Changxing Hospital, the Second Affiliated Hospital, Zhejiang University School of Medicine, Changxing 313100, Zhejiang Province, China.
Publication Type:Journal Article
MeSH: Adrenal Cortex Hormones; adverse effects; therapeutic use; Anti-Bacterial Agents; therapeutic use; Antiviral Agents; adverse effects; therapeutic use; Betacoronavirus; isolation & purification; Coronavirus Infections; drug therapy; Critical Illness; Drug Therapy; Humans; Nutritional Support; Pandemics; Pneumonia, Viral; drug therapy; Probiotics; administration & dosage
From: Journal of Zhejiang University. Medical sciences 2020;49(2):158-169
CountryChina
Language:Chinese
Abstract: Severe and critically ill patients with coronavirus disease 2019 (COVID-19) were usually with underlying diseases, which led to the problems of complicated drug use, potential drug-drug interactions and medication errors in special patients. Based on ( 6), and -19: , we summarized the experience in the use of antiviral drugs, corticosteroids, vascular active drugs, antibacterial, probiotics, nutrition support schemes in severe and critically ill COVID-19 patients. It is also suggested to focus on medication management for evaluation of drug efficacy and duration of treatment, prevention and treatment of adverse drug reactions, identification of potential drug-drug interactions, individualized medication monitoring based on biosafety protection, and medication administration for special patients.